{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:13Z","timestamp":1792184653092,"version":"4.4.0"},"reference-count":34,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852921000870_sec1\"><jats:title>Background<\/jats:title><jats:p>Despite frequent benzodiazepine use in anxiety disorders, the trajectory and magnitude of benzodiazepine response and the effects of benzodiazepine potency, lipophilicity, and dose on improvement are unknown.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000870_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>We performed a meta-analysis using weekly symptom severity data from randomized, parallel group, placebo-controlled trials of benzodiazepines in adults with anxiety disorders. Response was modeled for the standardized change in continuous measures of anxiety using a Bayesian hierarchical model. Change in anxiety was evaluated as a function of medication, disorder, time, potency, lipophilicity, and standardized dose and compared among benzodiazepines.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000870_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Data from 65 trials (73 arms, 7 medications, 7110 patients) were included. In the logarithmic model of response, treatment effects emerged within 1 week of beginning treatment (standardized benzodiazepine-placebo difference = \u22120.235 \u00b1 0.024, CrI: \u22120.283 to \u22120.186, <jats:italic>P<\/jats:italic> &lt; .001) and placebo response plateaued at week 4. Doses &lt;6 mg per day (lorazepam equivalents) produced faster and larger improvement than higher doses (<jats:italic>P<\/jats:italic> = .039 for low vs medium dose and <jats:italic>P<\/jats:italic> = .005 for high vs medium dose) and less lipophilic benzodiazepines (beta = 0.028 \u00b1 0.013, <jats:italic>P<\/jats:italic> = .030) produced a greater response over time. Relative to the reference benzodiazepine (lorazepam), clonazepam (beta = \u22120.217 \u00b1 0.95, <jats:italic>P<\/jats:italic> = .021) had a greater trajectory\/magnitude of response (other specific benzodiazepines did not statistically differ from lorazepam).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852921000870_sec4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>In adults with anxiety disorders, benzodiazepine-related improvement emerges early, and the trajectory and magnitude of improvement is related to dose and lipophilicity. Lower doses and less lipophilic benzodiazepines produce greater improvement.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852921000870","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T08:41:48Z","timestamp":1633077708000},"page":"53-60","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis"],"prefix":"10.1017","volume":"28","author":[{"given":"Julia N.","family":"Stimpfl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2641","authenticated-orcid":false,"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"S1092852921000870_r16","doi-asserted-by":"publisher","DOI":"10.1002\/da.22329"},{"key":"S1092852921000870_r28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00934-X"},{"key":"S1092852921000870_r14","first-page":"114","article-title":"Systematic review of benzodiazepines for anxiety disorders in late life","volume":"32","author":"Gupta","year":"2020","journal-title":"Ann Clin Psychiatry"},{"key":"S1092852921000870_r5","doi-asserted-by":"publisher","DOI":"10.1177\/02698811030173009"},{"key":"S1092852921000870_r32","first-page":"4","article-title":"Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications","volume":"54","author":"Greenblatt","year":"1993","journal-title":"J Clin Psych."},{"key":"S1092852921000870_r11","first-page":"75","article-title":"Benzodiazepine: an update on their mechanisms of action","volume":"3","author":"Nelson","year":"1996","journal-title":"Can J Clin Pharmacol"},{"key":"S1092852921000870_r21","doi-asserted-by":"publisher","DOI":"10.1002\/da.23064"},{"key":"S1092852921000870_r29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22106"},{"key":"S1092852921000870_r31","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324060-00003"},{"key":"S1092852921000870_r15","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S1092852921000870_r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2018.01.015"},{"key":"S1092852921000870_r34","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(93)90013-I"},{"key":"S1092852921000870_r8","first-page":"CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852921000870_r24","first-page":"1682","article-title":"Turing: a language for flexible probabilistic inference","volume":"84","author":"Ge","year":"2018","journal-title":"Proc Twenty-First Int Conf Artif Intell Stat."},{"key":"S1092852921000870_r30","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb03526.x"},{"key":"S1092852921000870_r7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31793-8"},{"key":"S1092852921000870_r12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1986.tb08975.x"},{"key":"S1092852921000870_r26","first-page":"CD001846","article-title":"Benzodiazepines for generalised anxiety disorder (GAD)","volume":"11","author":"Gale","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852921000870_r25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"S1092852921000870_r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7399"},{"key":"S1092852921000870_r13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118822146"},{"key":"S1092852921000870_r17","doi-asserted-by":"publisher","DOI":"10.1080\/07474939208800232"},{"key":"S1092852921000870_r1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1491966"},{"key":"S1092852921000870_r22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"S1092852921000870_r9","first-page":"CD011567","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","volume":"9","author":"Bighelli","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"S1092852921000870_r2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.7.681"},{"key":"S1092852921000870_r27","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107077355"},{"key":"S1092852921000870_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.03.077"},{"key":"S1092852921000870_r4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12101353"},{"key":"S1092852921000870_r18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006943009192"},{"key":"S1092852921000870_r23","doi-asserted-by":"publisher","DOI":"10.1137\/141000671"},{"key":"S1092852921000870_r20","article-title":"Buspirone in children and adolescents with anxiety: a review and Bayesian analysis of abandoned randomized controlled trials","volume":"28","author":"Strawn","year":"2017","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"S1092852921000870_r6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.580858"},{"key":"S1092852921000870_r10","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852921000870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T03:27:12Z","timestamp":1677036432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852921000870\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1092852921000870"],"URL":"https:\/\/doi.org\/10.1017\/s1092852921000870","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}